Stuart H. Isaacson, MD, FAAN

Dr. Isaacson discusses how health care providers can effectively balance the pharmacological properties of approved therapies for Parkinson's disease with patient preferences and comfort levels by fostering open communication and individualized care approaches.

Dr. Isaacson discusses how physicians can effectively integrate wellness strategies such as nutrition and exercise into treatment plans for Parkinson's disease (PD), encourage patient adherence to these habits alongside pharmacological therapy, and leverage advocacy groups as vital resources for both patients and health care professionals (HCPs) in navigating wellness and care management.

Dr. Isaacson discusses the challenges of delivering patient-centric care to individuals with Parkinson's disease (PD), alongside the evidence supporting improved symptom management through the combination of pharmacological therapies and wellness strategies.

Dr. Isaacson discusses how patient-centric, personalized care in Parkinson's Ddisease (PD) focuses on tailoring treatment to individual patient needs and preferences, contrasting with pharmacological-centered care by emphasizing shared decision-making and the holistic integration of wellness strategies.

Stuart Isaacson, MD, Rajesh Pahwa, MD, and Jennifer Goldman, MD discuss optimizing PD treatment with levodopa and adjunct therapies, addressing patient and pharmacologic challenges, coordinating care, and anticipating the impact of emerging therapies and upcoming Medicare Part D changes.

Stuart Isaacson, MD, Rajesh Pahwa, MD, and Jennifer Goldman, MD discuss optimizing PD treatment with levodopa and adjunct therapies, addressing patient and pharmacologic challenges, coordinating care, and anticipating the impact of emerging therapies and upcoming Medicare Part D changes.

Drs Isaacson, Pahwa, and Gupta discuss the management of dyskinesia and providing good ON time in Parkinson’s disease, sharing practical tips for early identification and treatment of dyskinesia, as well as their experience with current treatments.

Drs Isaacson, Pahwa, and Gupta discuss the management of dyskinesia and providing good ON time in Parkinson’s disease, sharing practical tips for early identification and treatment of dyskinesia, as well as their experience with current treatments.

The neurology experts discuss the importance of early and accurate diagnosis of Parkinson’s disease, the role of alpha-synuclein in the diagnosis of synucleinopathies and approaches to implementing screening protocols in clinical practice.

The neurology experts discuss the importance of early and accurate diagnosis of Parkinson’s disease, the role of alpha-synuclein in the diagnosis of synucleinopathies and approaches to implementing screening protocols in clinical practice.

Expert neurologists discuss strategies to widen the therapeutic window of Parkinson’s disease and options available to treat dyskinesia, providing better control of Parkinson’s disease.

Expert neurologists discuss strategies to widen the therapeutic window of Parkinson’s disease and options available to treat dyskinesia, providing better control of Parkinson’s disease.

The expert neurologists discuss non-motor symptoms of Parkinson’s disease: types, their impact on patient’s quality of life, and current and emerging treatment options for non-motor symptoms.

The expert neurologists discuss non-motor symptoms of Parkinson’s disease: types, their impact on patient’s quality of life, and current and emerging treatment options for non-motor symptoms.

The neurology doctors discuss motor fluctuations and dyskinesia associated with Parkinson’s Disease.

The neurology doctors discuss motor fluctuations and dyskinesia associated with Parkinson’s Disease.

Stuart H. Isaacson, MD, FAAN, speaks to the current understanding of genetics and other factors in the individualization of care for patients with Parkinson disease.

Stuart H. Isaacson, MD, FAAN, offers insight into the challenges faced when attempting to achieve long-term symptom control for patients with Parkinson disease.

An expert in the management of Parkinson disease discusses the key role that shared decision-making plays in the modern treatment paradigm.

Stuart H. Isaacson, MD, FAAN, offers insight into the importance of tailoring care to the individual when it comes to managing patients with Parkinson disease.

As therapeutic development has advanced in Parkinson disease management, the introduction of on-demand options have extended ON time for patients and altered the paradigm of care.

Expert neurologist highlights ongoing research in newer mechanisms of action and modes of delivery for treatments of Parkinson’s disease and OFF episodes.

Stuart Isaacson, MD, FAAN, evaluates the current treatment paradigm and highlights new, ‘on-demand’ medication for management of OFF episodes in Parkinson’s disease.

Stuart Isaacson, MD, FAAN, discusses the pharmacological basis of OFF episodes in patients with Parkinson’s disease.

Expert neurologist reviews manifestations of OFF episodes and their impact on the quality of life of patients with Parkinson’s Disease.

Stuart Isaacson, MD, FAAN, defines the terminology of OFF episodes in Parkinson’s disease and what “OFF” means from a clinical perspective.

Drs Laxman Bahroo, Rajesh Pahwa, and Robert A. Hauser share advice for neurologists treating OFF episodes in Parkinson Disease.

Robert A. Hauser, MD, MBA; Laxman Bahroo, DO; and Rajesh Pahwa, MD, review emerging therapies in development for the management of OFF episodes in Parkinson Disease.

Experts in movement disorders explore the potential role of an apomorphine infusion device in the Parkinson Disease treatment landscape for patients suffering from OFF episodes.